Real-world bleeding risks of new anticoagulants similar to warfarin (or lower)
www.pulmccm.org
New-generation oral anticoagulants (NOACs) like dabigatran, rivaroxaban, and apixaban all had similar efficacy and bleeding risk compared to warfarin in the randomized trials that led to their FDA approval. That didn’t stop trial lawyers from filing bundles of lawsuits on behalf of patients experiencing hemorrhages after taking NOACs. (The large brand-name pharmaceutical manufacturers advertising new billion-dollar drugs are much better targets than the generic warfarin makers who eschew marketing and sell an old drug with well-known risks.)
Real-world bleeding risks of new anticoagulants similar to warfarin (or lower)
Real-world bleeding risks of new…
Real-world bleeding risks of new anticoagulants similar to warfarin (or lower)
New-generation oral anticoagulants (NOACs) like dabigatran, rivaroxaban, and apixaban all had similar efficacy and bleeding risk compared to warfarin in the randomized trials that led to their FDA approval. That didn’t stop trial lawyers from filing bundles of lawsuits on behalf of patients experiencing hemorrhages after taking NOACs. (The large brand-name pharmaceutical manufacturers advertising new billion-dollar drugs are much better targets than the generic warfarin makers who eschew marketing and sell an old drug with well-known risks.)